Please login to the form below
Oxford University
This page shows the latest Oxford University news and features for those working in and with pharma, biotech and healthcare.
Six UK universities receive grant for research into motor neurone disease
The universities involved in the ‘MND Collaborative Partnership’ – King’s College London, University of Sheffield, University of Liverpool, University College London, University of Oxford and University of Edinburgh – will pool their
Latest news
-
Results released from new study of AstraZeneca’s COVID-19 antibody
A new study from Oxford University shows that Evusheld is effective in protecting against emerging Omicron variants. ... According to new preclinical data from the University of Oxford, AstraZeneca’s Evusheld, AZD7442, is effective in protecting
-
Results from trial show Eli Lilly’s COVID-19 drug improves survival rates
A trial led by The University of Oxford has shown that Eli Lilly and Incyte’s jointly developed drug, baricitinib, improves survival rates when given to patients hospitalised with severe ... RECOVERY trial joint chief investigator Sir Martin Landray,
-
AstraZeneca’s Vaxzevria trial provides further support for protection against COVID-19 variants
Professor Sir Andrew Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said: “These important studies show that a third dose of Vaxzevria after two ... The Oxford-AstraZeneca vaccine is suitable as an
-
UK marks one-year anniversary of Oxford/AstraZeneca vaccine
It has been one year since the first dose of the Oxford University/AstraZeneca COVID-19 vaccine was administered, making the UK the first country in the world to do so. ... The first recipient outside clinical trials, 82-year-old Brian Pinker, was given
-
UK supercharges booster programme over Omicron
While these are early data, a study from the University of Oxford has reported that current vaccines induced lower levels of neutralising antibodies against Omicron. ... Professor Gavin Screaton, head of the University’s medical sciences division said:
More from news
Approximately 34 fully matching, plus 183 partially matching documents found.
Latest Intelligence
-
Rare genetic diseases – what’s in store for 2021?
So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University vaccines have all received approval in the UK and other countries for the very disease that put all these changes into
-
COVID-19: the race to find a vaccine
Multiple groups are advancing vaccines based on similar technology. University of Oxford researchers are enrolling volunteers in a trial of its adenovirus vaccine, while Johnson &Johnson and the US government have
-
Developing a COVID-19 vaccine
Researchers from Oxford University have also said they plan to start clinical trials of their COVID-19 vaccine this month. ... The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax,
-
War games: why brand teams need a cunning plan that cannot fail
Who knows, it might well have been ‘as cunning as a fox who’d just been appointed Professor of Cunning at Oxford University’ – but his comrades never got to hear it
-
Biotech profile: Tom Evans, CEO, Vaccitech.
Vaccitech was launched in a spin-out from Oxford University in May 2016, with the aim of using its novel technology platform to develop a range of innovative new vaccines. ... You took the helm of Vaccitech when it was spun out Oxford University
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Amanda Pritchard becomes NHS England’s first female chief executive
She first joined the NHS as a graduate management trainee in 1997 after graduating from Oxford University.
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ian Walmsey, Pro-Vice-Chancellor Research &Innovation at the University of Oxford and Chair of the RFI’s Interim Board said: “I am delighted that Vivienne has agreed to be the ... I’ve seen how siloed some parts of science and corporate R&D can be
-
Paul Stockdale joins Oxford BioDynamics as CFO
He takes over from Katie Long, who has returned to her role within Tessera Investment Management, having previously established and led Oxford BioDynamics’ finance function. ... A spin-out from Oxford University, Oxford BioDynamics focuses on the
-
Martin Reeves joins Oxford BioDynamics
He takes up a senior vice president role. Oxford BioDynamics – a spin out company from the University of Oxford – has appointed Martin Reeves as its new senior vice president, commercial development. ... Christian Hoyer Millar, CEO at Oxford
-
Consilium appoints executive consultants
Standage (pictured right) joins the strategic healthcare communications firm from the University of Cambridge Judge Business School, having recently graduated with a degree in modern languages and management studies. ... Meanwhile Phillips (pictured left)
More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
One group involved in this area of research was the team at Oxford University, who’s efforts eventually became the Oxford-AstraZeneca vaccine currently in circulation. ... In the past year, we have seen partnerships between companies such as Pfizer and
-
Communicating the vaccine: how do we get the story right?
How significant are the barriers? According to a recent poll conducted by the University of Oxford, while a substantial majority (72%) are in favour of a COVID-19 vaccine, 16% of
-
Is the world ready for a COVID-19 vaccine?
Since this initial announcement, other good news in vaccine development has followed, with companies and collaborations, including Moderna and the AstraZeneca/University of Oxford team, publishing similarly positive trial results.
-
September 2020: diversity and inclusion in clinical trials round-up
population. There is the same problem in Europe.” Luis E. Raez, MD, of Memorial Cancer Institute/Florida International University in Miami, one of the co-authors. ... The trial is taking place in the UK, led by the University of Oxford.
-
Oxford University Press
Oxford University Press adds new innovative ePrint options to its product portfolio for healthcare marketing and education. ... Oxford University Press advertising and custom content team hosts their first ever virtual drop-in sessions.
More from PMHub
Approximately 0 fully matching, plus 25 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- The Evolving Role of the Sales Rep
- Measure your omnichannel maturity with our new tool
- Report: Omnichannel advice for the life science industry
- Gilead Sciences supports Kigali Declaration for neglected tropical diseases
- As the NHS turns 74, it launches its ‘biggest NHS Big Tea ever’ to raise funds
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
